 |
| Research article summary (published 7 Apr 2009): |
Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis.
Full Abstract
In kidney injury the accumulation of extracellular matrix (ECM) plays an important role and precedes the development of glomerulosclerosis (GS). There is great interest in agents that may interfere with such accumulation of ECM. Therefore, a rat model of GS was established to investigate the effect of all-trans retinoic acid (ATRA) on the renal expressions of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1). Eighty Wistar rats were randomly divided into four groups: sham operation group (SHO), GS model group without treatment (GS), GS model group treated with benazepril (GB) and GS model group treated with ATRA (GA), n = 20, respectively. The disease was established in the GS rats by uninephrectomy and adriamycin (5 mg/kg) injection through the tail vein. Serum creatinine (Scr), blood urea nitrogen (BUN) and urine protein (Upro) were measured. Renal abnormality was evaluated at the end of 12 weeks. Immunohistochemical analysis was performed on renal tissue to detect the expression of collagen IV (Col-IV), fibronectin (FN), MMP-2, MMP-9 and TIMP-1 protein. MMP-2 and MMP-9 activity was detected by gelatin zymography. Real-time reverse transcription polymerase chain reaction (real-time RT-PCR) was used to detect the expression of MMP-2, MMP-9, and TIMP-1 mRNA. In comparison with group GS, group GA and group GB exhibited levels of BUN and 24 h urinary protein and a glomerulosclerosis index (GSI) that were significantly reduced (P < 0.05); the level of Scr in group GA was reduced too (P < 0.05). ATRA and benazepril also significantly down-regulated Col-IV, FN expression and TIMP-1 expression (protein and mRNA) (P < 0.05). In contrast, the expressions of MMP-2, MMP-9 mRNA and protein, and activity in groups GA and GB were enhanced (P < 0.05). However, there were no significant differences in MMP-2, MMP-9 mRNA and protein expression, or activity, between the ATRA and GB groups (P > 0.05). In conclusion, ATRA may protect renal function and step down the progression of GS by reducing the expression of TIMP-1, enhancing the expression and activity of MMP-2 and MMP-9, and regulating the ratio of MMPs/TIMPs to dynamic balance, so as to reduce the accumulation of ECM.
Author information
Author/s: Qin, Yuan-Han (YH); Lei, Feng-Ying (FY); Hu, Peng (P); Pei, Juan (J); Feng, Zhen-Bo (ZB); Pang, Yu-Sheng (YS);
Affiliation: Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China. qinyuanhan603(-atsign-)yahoo.com.cn
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal: Pediatric nephrology (Berlin, Germany) (Pediatr Nephrol), published in Germany. (Language: eng)
Reference: 2009-Aug; vol 24 (issue 8) : pp 1477-86
Dates: Created 2009/06/17; Completed 2009/08/24;
PMID: 19357873, status: MEDLINE (last retrieved date: 8/24/2009)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MeSH Headings (categories) shown below.
Note: Bold headings indicate primary MeSH headings or qualifiers.
Associated Chemicals: Tissue Inhibitor of Metalloproteinase-1 (0) ; Tretinoin (302-79-4) ; Matrix Metalloproteinase 2 (EC 3.4.24.24) ; Matrix Metalloproteinase 9 (EC 3.4.24.35)Related articles
These are the most related articles currently in our database:
- Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space.
14 Apr 2008 - [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix] 29 Jun 2002
- All trans-retinoic acid selectively down-regulates matrix metalloproteinase-9 (MMP-9) and up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) in human bronchoalveolar lavage cells.
30 Mar 2001 - Dynamic in vivo changes in tissue inhibitors of metalloproteinases 1 and 2, and matrix metalloproteinases 2 and 9, during prostaglandin F(2alpha)-induced luteolysis in sheep. 29 Apr 2002
- Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. 13 Aug 2007
- Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization. 30 Oct 2001
- Regulation of matrix metalloproteinase expression by estrogen in fibroblasts that are derived from the pelvic floor. 29 Jun 2002
- The effect of endothelial cell overexpression of plasminogen activator inhibitor-1 on smooth muscle cell migration. 29 Jun 2002
- MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. 8 Oct 2006
- Gelatinase and inhibitor expression in soft tissue sarcomas: lack of correlation with distant metastasis. 30 Jul 2000
Related Article Map
7/30/2000
4/14/2008
Higher Relevance Score (100)
Lower Relevance Score (64)
Legend: - FREE Full text Article. - Abstract only. 
- Title only. More help.
See a larger map of 100+ related articles.